Development and validation of RP-HPLC method for determination of Atorvastatin calcium (cas 134523-03-8) and Nicotinic acid in combined tablet dosage form

Add time:08/05/2019    Source:sciencedirect.com

A simple, specific and accurate reverse phase liquid chromatographic method was developed for the simultaneous determination of Atorvastatin calcium (cas 134523-03-8) and Nicotinic acid in tablet dosage forms. The analysis has been performed by using Agilent ZORBAX SB-C18 (150 × 4.6 mm, 3.5 u) and mobile phase containing acetonitrile: distilled water (85:15) at pH 4.5 (adjusted with phosphoric acid). The detection was carried out at 261 nm with a flow rate of 1.0 ml/min. The retention times of Atorvastatin calcium and Nicotinic acid were 6.092 and 3.125 min, respectively. The method was validated according to ICH guidelines. The method was validated for specificity, precision, linearity, accuracy and robustness. The linearity for Atorvastatin calcium and Nicotinic acid were in the range of 2–12 and 10–80 μg/ml respectively. The recoveries of Atorvastatin calcium and Nicotinic acid were found to be in the range of 99.031% and 99.744% respectively. The proposed method was validated and successfully applied to the estimation of Atorvastatin calcium and Nicotinic acid in combined tablet formulation.

We also recommend Trading Suppliers and Manufacturers of Atorvastatin calcium (cas 134523-03-8). Pls Click Website Link as below: cas 134523-03-8 suppliers

Prev:Atorvastatin calcium (cas 134523-03-8) in combination with methylprednisolone for the treatment of multiple sclerosis relapse
Next:Physicochemical characteristics of the complexes of simvastatin and Atorvastatin calcium (cas 134523-03-8) with hydroxypropyl-β-cyclodextrin produced by mechanochemical activation)